IOBT IO Biotech
- 0.927
- -0.123-11.68%
- 0.902
- -0.025-2.71%
IO Biotech News
TD Cowen Maintains IO Biotech(IOBT.US) With Buy Rating
Promising Clinical Progress and Financial Stability Drive Buy Rating for IO Biotech
IO Biotech Analyst Ratings
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $12
IO Biotech Receives Buy Rating Amid Promising Phase 2 Results and Future Potential in Cancer Treatments
Jefferies Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $8
IO Biotech Is Maintained at Overweight by Morgan Stanley
IO Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $12 Price Target
Piper Sandler Sticks to Its Buy Rating for IO Biotech (IOBT)
Buy Rating for IO Biotech Backed by Promising ESMO Data and Superior Efficacy of IO102-IO103 Combination Therapy
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $4
IO Biotech Analyst Ratings
H.C. Wainwright Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Cuts Target Price to $4
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $7
IO Biotech Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Analysis
Price Target
No Data
No Data